Effectiveness of piperonyl butoxide and pyrethroid-treated long-lasting insecticidal nets (LLINs) versus pyrethroid-only LLINs with and without indoor residual spray against malaria infection: third year results of a cluster, randomised controlled, two-by-two factorial design trial in Tanzania.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
03 Oct 2023
Historique:
received: 29 03 2023
accepted: 25 09 2023
medline: 5 10 2023
pubmed: 4 10 2023
entrez: 3 10 2023
Statut: epublish

Résumé

After decades of success in reducing malaria through the scale-up of pyrethroid long-lasting insecticidal nets (LLINs), the decline in the malaria burden has stalled, coinciding with the rapid spread of pyrethroid resistance. In a previously reported study, nets treated with a pyrethroid and a synergist, piperonyl butoxide (PBO), demonstrated superior efficacy compared to standard pyrethroid LLINs (std-LLINs) against malaria. Evidence was used to support the public health recommendation of PBO-Pyrethroid-LLIN by the World Health Organization in 2018. This study looks at the third year of rollout of these nets in Muleba district, Tanzania to inform whether policy guidelines need to be updated. A four-group cluster randomized trial (CRT) using a two-by-two factorial design was carried out between January 2014 and December 2017. A total of 48 clusters, were randomized in a 1:1:1:1 ratio to the following treatment groups, each intervention being provided once in 2015: 1/std-LLIN; 2/PBO-pyrethroid LLIN; 3/std-LLIN + Indoor Residual Spraying (IRS) and 4/PBO-Pyrethroid-LLIN + IRS. During the third year follow-up, malaria infection prevalence in 80 children per cluster, aged 6 months to 14 years, was measured at 28- and 33-months post-intervention and analysed as intention-to-treat (ITT) and per protocol (PP). Mosquito collections were performed monthly in all clusters, using CDC light traps in 7 randomly selected houses per cluster. At 28 and 33 months, study net usage among household participants was only 47% and 31%, respectively. In ITT analysis, after 28 months malaria infection prevalence among 7471 children was 80.9% in the two std-LLIN groups compared to 69.3% in the two PBO-Pyrethroid-LLIN (Odds Ratio: 0.45, 95% Confidence Interval: 0.21-0.95, p-value: 0.0364). After 33 months the effect was weaker in the ITT analysis (prevalence 59.6% versus 49.9%, OR: 0.60, 95%CI:0.32-1.13, p-value: 0.1131) but still evident in the PP analysis (57.2% versus 44.2%, OR: 0.34, 95%CI: 0.16-0.71, p-value: 0.0051). Mean number of Anopheles per night collected per house was similar between PBO-Pyrethroid-LLIN groups (5.48) and std-LLIN groups (5.24) during the third year. Despite low usage of PBO- Pyrethroid LLIN, a small impact of those nets on malaria infection prevalence was still observed in the 3rd year with the most protection offered to children still using them. To maximize impact, it is essential that net re-distribution cycles are aligned with this LLIN lifespan to maintain maximum coverage. The trial was registered with ClinicalTrials.gov (registration number NCT02288637).

Sections du résumé

BACKGROUND BACKGROUND
After decades of success in reducing malaria through the scale-up of pyrethroid long-lasting insecticidal nets (LLINs), the decline in the malaria burden has stalled, coinciding with the rapid spread of pyrethroid resistance. In a previously reported study, nets treated with a pyrethroid and a synergist, piperonyl butoxide (PBO), demonstrated superior efficacy compared to standard pyrethroid LLINs (std-LLINs) against malaria. Evidence was used to support the public health recommendation of PBO-Pyrethroid-LLIN by the World Health Organization in 2018. This study looks at the third year of rollout of these nets in Muleba district, Tanzania to inform whether policy guidelines need to be updated.
METHODS METHODS
A four-group cluster randomized trial (CRT) using a two-by-two factorial design was carried out between January 2014 and December 2017. A total of 48 clusters, were randomized in a 1:1:1:1 ratio to the following treatment groups, each intervention being provided once in 2015: 1/std-LLIN; 2/PBO-pyrethroid LLIN; 3/std-LLIN + Indoor Residual Spraying (IRS) and 4/PBO-Pyrethroid-LLIN + IRS. During the third year follow-up, malaria infection prevalence in 80 children per cluster, aged 6 months to 14 years, was measured at 28- and 33-months post-intervention and analysed as intention-to-treat (ITT) and per protocol (PP). Mosquito collections were performed monthly in all clusters, using CDC light traps in 7 randomly selected houses per cluster.
RESULTS RESULTS
At 28 and 33 months, study net usage among household participants was only 47% and 31%, respectively. In ITT analysis, after 28 months malaria infection prevalence among 7471 children was 80.9% in the two std-LLIN groups compared to 69.3% in the two PBO-Pyrethroid-LLIN (Odds Ratio: 0.45, 95% Confidence Interval: 0.21-0.95, p-value: 0.0364). After 33 months the effect was weaker in the ITT analysis (prevalence 59.6% versus 49.9%, OR: 0.60, 95%CI:0.32-1.13, p-value: 0.1131) but still evident in the PP analysis (57.2% versus 44.2%, OR: 0.34, 95%CI: 0.16-0.71, p-value: 0.0051). Mean number of Anopheles per night collected per house was similar between PBO-Pyrethroid-LLIN groups (5.48) and std-LLIN groups (5.24) during the third year.
CONCLUSIONS CONCLUSIONS
Despite low usage of PBO- Pyrethroid LLIN, a small impact of those nets on malaria infection prevalence was still observed in the 3rd year with the most protection offered to children still using them. To maximize impact, it is essential that net re-distribution cycles are aligned with this LLIN lifespan to maintain maximum coverage.
TRIAL REGISTRATION BACKGROUND
The trial was registered with ClinicalTrials.gov (registration number NCT02288637).

Identifiants

pubmed: 37789389
doi: 10.1186/s12936-023-04727-8
pii: 10.1186/s12936-023-04727-8
pmc: PMC10548685
doi:

Substances chimiques

Insecticides 0
Piperonyl Butoxide LWK91TU9AH
Pyrethrins 0

Banques de données

ClinicalTrials.gov
['NCT02288637']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

294

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L004437/1
Pays : United Kingdom

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Evol Appl. 2017 Dec 04;11(4):431-441
pubmed: 29636797
PLoS One. 2022 Jan 24;17(1):e0249440
pubmed: 35073324
BMC Infect Dis. 2014 Feb 08;14:69
pubmed: 24507444
Lancet Infect Dis. 2023 Feb;23(2):247-258
pubmed: 36174592
Cochrane Database Syst Rev. 2021 May 24;5:CD012776
pubmed: 34027998
Infect Dis Poverty. 2021 Dec 20;10(1):135
pubmed: 34930459
Am J Trop Med Hyg. 1984 Sep;33(5):783-8
pubmed: 6385740
PLoS Med. 2007 Jul;4(7):e229
pubmed: 17608562
Lancet. 2018 Apr 21;391(10130):1577-1588
pubmed: 29655496
Am J Trop Med Hyg. 2003 Apr;68(4 Suppl):121-7
pubmed: 12749495
Curr Res Parasitol Vector Borne Dis. 2022 May 25;2:100092
pubmed: 35734077
Am J Trop Med Hyg. 2021 Jun 14;105(2):461-471
pubmed: 34125699
Acta Trop. 2008 Jul;107(1):50-3
pubmed: 18490000
Sci Rep. 2022 Apr 27;12(1):6857
pubmed: 35478216
Malar J. 2017 Aug 15;16(1):336
pubmed: 28810872
Lancet. 2020 Apr 18;395(10232):1292-1303
pubmed: 32305094
PLoS Med. 2020 Sep 18;17(9):e1003248
pubmed: 32946451
PLOS Glob Public Health. 2022 Oct 17;2(10):e0000453
pubmed: 36962517
Lancet. 2023 Feb 11;401(10375):435-446
pubmed: 36706778
Lancet. 2018 Aug 18;392(10147):569-580
pubmed: 30104047
Parasit Vectors. 2021 Mar 10;14(1):150
pubmed: 33691742
Lancet. 2022 Mar 26;399(10331):1227-1241
pubmed: 35339225
Malar J. 2015 Jan 21;14:18
pubmed: 25604427
BMJ Open. 2021 Mar 8;11(3):e046664
pubmed: 34006037
Malar J. 2020 Apr 17;19(1):158
pubmed: 32303240
Malar J. 2021 Jan 7;20(1):26
pubmed: 33413388
Lancet Planet Health. 2022 Feb;6(2):e100-e109
pubmed: 35065707
Malar J. 2020 Jun 17;19(1):209
pubmed: 32552819
Malar J. 2023 Feb 7;22(1):46
pubmed: 36747225
BMC Infect Dis. 2021 Feb 19;21(1):194
pubmed: 33607958
Malar J. 2017 Oct 2;16(1):394
pubmed: 28969632

Auteurs

Natacha Protopopoff (N)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK. natacha.protopopoff@lshtm.ac.uk.

Jacklin F Mosha (JF)

Mwanza Medical Research Centre, National Institute for Medical Research, Mwanza, Tanzania.

Louisa A Messenger (LA)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.

Eliud Lukole (E)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.
Mwanza Medical Research Centre, National Institute for Medical Research, Mwanza, Tanzania.

Jacques D Charlwood (JD)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.

Alexandra Wright (A)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.

Enock Kessy (E)

Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Alphaxard Manjurano (A)

Mwanza Medical Research Centre, National Institute for Medical Research, Mwanza, Tanzania.

Franklin W Mosha (FW)

Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Immo Kleinschmidt (I)

MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Southern African Development Community Malaria Elimination Eight Secretariat, Windhoek, Namibia.

Mark Rowland (M)

Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH